Press Release

Cold Genesys Announces Name Change to CG Oncology

– Name Change Emphasizes Company Vision and Mission to Combat Cancer –

IRVINE, Calif., March 25, 2020 – Cold Genesys, Inc. announced today the company is changing its name to CG Oncology, Inc. effective immediately. The name change reflects the company’s overall vision and mission to treat a variety of oncology conditions. CG Oncology is a clinical-stage immuno-oncology company developing an oncolytic immunotherapy to combat bladder cancer and other solid tumors.

“The re-naming of our company to CG Oncology reflects an important step in our journey to build a leading oncology therapeutic company,” said CG Oncology CEO Arthur Kuan. “We believe changing the name from Cold Genesys to CG Oncology will be far more universally accessible and emphasizes our goal to fight cancer globally. The name change will be incorporated across all aspects of our business in the relatively near future. This change also reflects CG Oncology's progress, as the company has achieved significant scientific and corporate milestones in recent years, and provides a clear and direct path in the years ahead. We are investing heavily in the growth of our company, and we are all striving to develop treatments that will ultimately change and save lives.”

Kuan added, “We continue development of our lead therapeutic candidate, CG0070, an oncolytic immunotherapy for the treatment of BCG-unresponsive, non-muscle-invasive bladder cancer. CG0070 is also being studied in other bladder cancer settings as well as other solid tumor types. In addition, different immune checkpoint inhibitors are being studied in combination with our oncolytic immunotherapy."

About CG Oncology

CG Oncology, previously known as Cold Genesys, is a clinical-stage immuno-oncology company focused on the development of oncolytic immunotherapies to combat cancer. The company’s lead candidate CG0070 has completed an investigation in a Phase 2, single-arm, open-label, multicenter study (BOND2) for patients with non-muscle invasive bladder cancer (NMIBC) who failed BCG therapy and refused cystectomy. In addition, CG Oncology is exploring the use of CG0070 in combination with immune checkpoint inhibitors in different solid tumors. Learn more at www.cgoncology.com.

Contacts

Bing Kung
Vice President, Business Development
CG Oncology, Inc.
(949) 354-4246
bd@cgoncology.com